Triana Biomedicines
Updated: December 18, 2025
CEO - Patrick Trojer
Country: USA | Funding: $280.8M (+)
Founded: 2019
Website: https://trianabio.com
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
Founded: 2019
Website: https://trianabio.com
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
